Last week President Trump asked pharmaceutical companies to reveal "real prices" in his State of the Union address. This stems from an administration proposal that would require drugmakers to show full prices of medicines in TV ads.
Johnson & Johnson has taken up the call and will start stating prices with ads for blood thinner Xarelto by March. Johnson & Johnson’s planned price disclosure will include an estimate of what typical patients actually pay for drugs, something that Trump’s proposed mandate doesn’t include. Big pharma generally opposes the idea, arguing that list prices are meaningless to most Americans because health plans often negotiate huge discounts with drugmakers and consumers usually pay only a portion of a lower price themselves.
JNJ moved below its 50-day moving average on May 17, 2023 date and that indicates a change from an upward trend to a downward trend. In of 46 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on May 04, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on JNJ as a result. In of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for JNJ turned negative on April 26, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .
The 10-day moving average for JNJ crossed bearishly below the 50-day moving average on May 23, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for JNJ entered a downward trend on May 22, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 16 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
JNJ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.659) is normal, around the industry mean (6.139). P/E Ratio (32.362) is within average values for comparable stocks, (30.248). Projected Growth (PEG Ratio) (3.654) is also within normal values, averaging (3.483). Dividend Yield (0.030) settles around the average of (0.027) among similar stocks. P/S Ratio (4.248) is also within normal values, averaging (4.024).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. JNJ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
an investment holding company with interests in health care products
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with MRK. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then MRK could also see price increases.